Cognitive Impairment and Outcome of Acute Ischemic Stroke.

Mansoura University Hospital

Status: Completed

Conditions: Ischemic Stroke; Cognitive Impairment; Outcome, Fatal

Treatments: Diagnostic Test: Montreal Cognitive Assessment (MoCA)

Study type: Observational

Funder types: Other

Identifiers

NCT04235920

Mansoura University 12

Details and patient eligibility

About

The aim of this study is to assess the use of ASPECTS and stroke biomarkers to predict the outcome and cognitive impairment in acute ischemic stroke.

Full description

150 patients (79 males, and 71 females with a mean age of 64.05±11.55 years) were included in this study presented by acute middle cerebral artery territory ischemic stroke. Vascular risk factors were determined from the history taking. Assessment of GCS and NIHSS at the initial presentation was done to assess the stroke severity. Cognitive functions were evaluated in all study participants by the Montreal Cognitive Assessment (MoCA) Arabic version. An initial and follow up non-contrast CT brain was done after 7 days which were assessed by ASPECTS. Functional outcomes in stroke cases were assessed after three months by Glasgow Coma Scale, National Institutes of Health Stroke Scale and modified Rankin Scale. Biomarkers of cognitive impairment like ESR, CRP, S100B, MMP9 and glutamate were evaluated.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• First attack of acute MCA territory infarction within 2 days from the onset.

Exclusion criteria

• previous stroke,
• presence of anterior cerebral artery infarction,
• posterior cerebral artery infarction, and
• venous infarction.

Trial design

150 participants in 2 patient groups

Impaired Cognition

Description:

First group was cognitively impaired test with MoCA score of 25 or less.

Treatment:

Diagnostic Test: Montreal Cognitive Assessment (MoCA)

Preserved cognition

Description:

The second group was cognitively preserved with MoCA score of higher than 25.

Treatment:

Diagnostic Test: Montreal Cognitive Assessment (MoCA)